South Korea has added Gilead Sciences' remdesivir to its COVID-19 treatment guidelines and has urged caution in regards to using the steroid therapy dexamethasone, as reported by the International Business Times.
The country's updated guidelines come after a study showed that dexamethasone reduced deaths in severely ill COVID-19 patients. They advised doctors to take caution until a full study is published.
"It seems appropriate to administer (dexamethasone), limited to severe cases with the acute respiratory syndrome, as the doctor monitors the patient's condition," said Kim Young-ok, director-general of pharmaceutical safety bureau at the Ministry of Food and Drug Safety.
There was enough domestic supply of the dexamethasone, with production of approximately 43 million tablets and 60 million injection ampoules a year, said Kim.
Meanwhile, Korean health authorities also advised the dropping of hydroxychloroquine after a study found the malaria drug did not provide any benefit.
To read more NewsPoints articles, click here.